Simultaneous Determination of Sumatriptan Succinate and Naproxen Sodium by Reversed‐Phase High‐Performance Liquid Chromatography in Pharmaceutical Formulations Using Deep Eutectic Solvent for Micro‐Extraction

ABSTRACT The study deals with the quantification of sumatriptan succinate and naproxen sodium in combined pharmaceutical formulations by reversed‐phase high‐performance liquid chromatography. The drugs were extracted with deep eutectic solvent prior to analysis. The parameters that affected the area and separation of chromatographic peaks were optimized and the method was validated. The deep eutectic solvent was mixture of choline chloride and phenol (1:2 g/g) dissolved in 50 mL of distilled water, of which 2 mL was employed for drug extraction, having phosphate buffer of pH 8. The organic solvent used for drug dissolution was 10% v/v solution of acetic acid in chloroform, while the mobile phase was a solution of acetonitrile (65%), water (34%), and acetic acid (1%) by volume. The optimum separation of peaks was achieved using C18 column with an ultraviolet detector at wavelength of 275 nm and flow rate of 1.0 mL/min in isocratic mode. The linearity range of sumatriptan succinate was 10–120 µg/mL with correlation coefficient of 0.9986, while that of naproxen sodium was 10–50 µg/mL with correlation coefficient of 0.9991. The limit of detection and limit of quantitation for sumatriptan succinate were 1.066 and 3.232 µg/mL, respectively, while those for naproxen sodium were 1.065 and 3.228 µg/mL, respectively. The % relative standard deviation of accuracy, intra‐day precision, and inter‐day precision was with in accepted range that is less than 2%. The method showed robustness and could be applied for the routine analysis of sumatriptan succinate and naproxen sodium in combined pharmaceutical formulations.